Tacrosolv

About Marinomed Biotech

Marinomed Biotech is a publicly traded biopharmaceutical company developing therapies in virology and immunology based on its patented Marinosolv® technology platform. Its pipeline includes clinical-stage programs for allergic rhinitis and viral infections, alongside commercial-stage medical devices. The company faces near-term financial pressures, as evidenced by recent capital measures, and is exploring strategic options for its core platform while advancing its key clinical asset, Budesolv.

Therapeutic Areas